Allosteric Bioscience Advances Integrated Platform To Decode And Control Molecular Drivers Of Aging

Allosteric Bioscience, Inc. is utilizing Genetics, Genomics, Systems Biology, Quantum Computing, Advanced Proprietary AI and Proprietary Molecular ...

March 06, 2026 | Friday | News
Ono and Congruence Deepen Strategic Discovery Alliance Beyond Oncology

Beginning a new drug discovery collaboration using Congruence’s globally recognized Revenir™ platform for the creation of small molecule ...

March 04, 2026 | Wednesday | News
Human-Centric AI: Accelerating Formulation Development Without Compromising Trust

As artificial intelligence becomes increasingly embedded in formulation science and early clinical planning, the industry faces a dual challenge: accelerat...

March 04, 2026 | Wednesday | Expert Opinion
Novo Nordisk Expands Sogroya® Label with Three New Pediatric Growth Disorder Indications

New indications expand treatment options for appropriate children aged 2.5 years and older with Idiopathic Short Stature (ISS), born Small for Ges...

March 03, 2026 | Tuesday | News
SciBase Holding AB Secures FDA Label Expansion to Broaden Clinical Use of Nevisense in U.S. Dermatology Practices

SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, announced that it has received appro...

March 03, 2026 | Tuesday | News
Redefining CNS Therapeutics: A Conversation with Joel Latham on Incannex Healthcare’s Clinical Vision

    Under the leadership of Joel Latham, Incannex Healthcare is advancing a differentiated pipeline of cannabinoid- and psychedelic-based thera...

March 02, 2026 | Monday | Interaction
Organon Strengthens Women’s Health Portfolio With Exclusive MIUDELLA Licensing Agreement

MIUDELLA® is a strategic addition to Organon’s portfolio, strengthening its long‑term commitment to advancing women’s health ...

February 25, 2026 | Wednesday | News
SkylineDx’s Merlin CP-GEP Becomes First Molecular Test Recognized in National Comprehensive Cancer Network Melanoma Guidelines for SLNB Risk Assessment

Merlin CP-GEP is the only molecular test recognized by NCCN as predictive and appropriate for use in select T1 and T2 patients to support shared d...

February 23, 2026 | Monday | News
Sōlaria Biō Reports Clinical Evidence Confirming Gut Delivery and Viability of Bōndia™ Synbiotic Medical Food for Bone Health

Sōlaria Biō, a biotechnology company pioneering natural solutions for healthy aging, recently published the findings of a new open-label, randomized cl...

February 23, 2026 | Monday | Reports
Hana Health by DSS Imagetech Partners with Overture Life to Introduce Automated Egg-Freezing Technology in India

For the first time in India, couples seeking In Vitro Fertilisation (IVF) treatment for conception can rely on a globally preferred, automated egg-freezi...

February 20, 2026 | Friday | News
Daiichi Sankyo and AstraZeneca Advance ENHERTU Toward EU Approval in Early Breast Cancer Following Landmark Phase 3 Risk Reduction Data

Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-D...

February 20, 2026 | Friday | News
DeciBio Consulting LLC Launches EU-5 Oncology Genomics Tracker, Revealing Adoption Trends and Precision Medicine Gaps

A new survey-based Genomics Tracker focused on the EU-5 (France, Germany, Italy, Spain, and the United Kingdom) by DeciBio Consulting LLC provides update...

February 18, 2026 | Wednesday | Reports
Alto Neuroscience, Inc. Completes Patient Enrollment in Phase 2 Trial of ALTO-101 for Schizophrenia-Related Cognitive Impairment

-Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medi...

February 16, 2026 | Monday | News
Neupulse Secures £3 Million Backing to Accelerate Non-Drug Treatment for Tourette Syndrome

Funding led by Eos Advisory and Midlands Engine Investment Fund II, through appointed fund  manager Mercia Ventures, signals strong investor confidenc...

February 16, 2026 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close